Item 1. Financial Statements

123K characters. Original on sec.gov · Markdown

Item 1. Financial Statements

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)


	March 28,		December 31,
(In millions except share and per share amounts)	2026		2025
Assets
Current assets:
Cash and cash equivalents	$	3,254	$	9,852
Short-term investments	2		253
Accounts receivable, less allowances of $149 and $147	9,204		8,900
Inventories	5,496		5,425
Contract assets, net	1,684		1,666

Other current assets	2,677		2,612
Total current assets	22,316		28,707
Property, plant and equipment, net	10,658		10,565
Acquisition-related intangible assets, net	19,146		15,838
Other assets	5,973		5,871
Goodwill	55,187		49,362
Total assets	$	113,281	$	110,343

Liabilities, redeemable noncontrolling interest and equity
Current liabilities:
Short-term obligations and current maturities of long-term obligations	$	3,090	$	3,533
Accounts payable	3,344		3,622
Accrued payroll and employee benefits	1,565		1,995
Contract liabilities	2,928		2,710
Other accrued expenses	3,694		3,329
Total current liabilities	14,621		15,189
Deferred income taxes	2,107		1,493
Other long-term liabilities	4,421		4,273
Long-term obligations	40,071		35,852
Redeemable noncontrolling interest	121		122
Equity:
Thermo Fisher Scientific Inc. shareholders’ equity:
Preferred stock, $100 par value, 50,000 shares authorized; none issued	—		—
Common stock, $1 par value, 1,200,000,000 shares authorized; 445,473,074 and 445,160,301 shares issued	445		445
Capital in excess of par value	18,713		18,563
Retained earnings	60,632		59,156
Treasury stock at cost, 73,851,609 and 68,938,831 shares	(25,360)		(22,309)
Accumulated other comprehensive income/(loss)	(2,497)		(2,448)
Total Thermo Fisher Scientific Inc. shareholders’ equity	51,934		53,407
Noncontrolling interests	7		7
Total equity	51,940		53,415
Total liabilities, redeemable noncontrolling interest and equity	$	113,281	$	110,343

The accompanying notes are an integral part of these condensed consolidated financial statements.

THERMO FISHER SCIENTIFIC INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)


	Three months ended
		March 28,		March 29,
(In millions except per share amounts)		2026		2025
Revenues
Product revenues		$	6,277	$	5,980
Service revenues		4,728		4,384
Total revenues		11,005		10,364
Costs and operating expenses:
Cost of product revenues		3,261		3,125
Cost of service revenues		3,314		3,004
Selling, general and administrative expenses		2,181		2,078
Research and development expenses		336		342
Restructuring and other costs		49		98
Total costs and operating expenses		9,142		8,648
Operating income		1,863		1,716
Interest income		233		203
Interest expense		(354)		(303)
Other income/(expense)		(9)		3
Income before income taxes		1,734		1,620
Benefit from/(provision for) income taxes		(70)		(95)
Equity in earnings/(losses) of unconsolidated entities		(8)		(14)
Net income		1,656		1,511
Less: net income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest		5		4
Net income attributable to Thermo Fisher Scientific Inc.		$	1,651	$	1,507

Earnings per share attributable to Thermo Fisher Scientific Inc.
Basic		$	4.44	$	3.99
Diluted		$	4.43	$	3.98

Weighted average shares
Basic		372		378
Diluted		373		379

The accompanying notes are an integral part of these condensed consolidated financial statements.

THERMO FISHER SCIENTIFIC INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)


	Three months ended
		March 28,		March 29,
(In millions)		2026		2025
Comprehensive income/(loss)
Net income		$	1,656	$	1,511
Other comprehensive income/(loss):
Cumulative translation adjustment:
Cumulative translation adjustment (net of tax provision (benefit) of $27 and $(207))		(58)		360



Unrealized gains/(losses) on hedging instruments:

Reclassification adjustment for losses included in net income (net of tax (provision) benefit of $0 and $0)		1		1
Pension and other postretirement benefit liability adjustments:
Pension and other postretirement benefit liability adjustments arising during the period (net of tax (provision) benefit of $(1) and $1)		2		(3)
Amortization of net loss included in net periodic pension cost (net of tax (provision) benefit of $0 and $0)		1		1
Total other comprehensive income/(loss)		(55)		358
Comprehensive income/(loss)		1,601		1,869
Less: comprehensive income/(loss) attributable to noncontrolling interests and redeemable noncontrolling interest		(1)		8
Comprehensive income attributable to Thermo Fisher Scientific Inc.		$	1,602	$	1,861

The accompanying notes are an integral part of these condensed consolidated financial statements.

THERMO FISHER SCIENTIFIC INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


	Three months ended
	March 28,		March 29,
(In millions)	2026		2025
Operating activities
Net income	$	1,656	$	1,511
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation of property, plant and equipment	306		276
Amortization of acquisition-related intangible assets	430		429
Change in deferred income taxes	(258)		(279)


Stock-based compensation	83		75
Other net non-cash expenses	88		135
Changes in assets and liabilities, excluding the effects of acquisitions	(1,112)		(1,425)
Net cash provided by operating activities	1,192		723
Investing activities

Purchases of property, plant and equipment	(376)		(362)
Proceeds from sale of property, plant and equipment	9		12
Proceeds from cross-currency interest rate swap interest settlements	96		87
Acquisitions, net of cash acquired	(8,872)		—
Purchases of investments	(14)		(264)
Proceeds from sales and maturities of investments	250		2
Other investing activities, net	(55)		(1)
Net cash used in investing activities	(8,961)		(527)
Financing activities
Net proceeds from issuance of debt	5,238		2,840
Repayment of debt	(1,412)		(838)
Proceeds from issuance of commercial paper	389		—

Purchases of company common stock	(3,000)		(2,000)
Dividends paid	(162)		(149)

Other financing activities, net	39		45
Net cash provided by (used in) financing activities	1,093		(102)
Exchange rate effect on cash	78		37
Increase/(decrease) in cash, cash equivalents and restricted cash	(6,599)		132
Cash, cash equivalents and restricted cash at beginning of period	9,879		4,040
Cash, cash equivalents and restricted cash at end of period	$	3,280	$	4,172

The accompanying notes are an integral part of these condensed consolidated financial statements.

THERMO FISHER SCIENTIFIC INC.

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND EQUITY

(Unaudited)


	Redeemable Noncontrolling Interest			Common Stock				Capital in Excess of Par Value			Retained Earnings			Treasury Stock			Accumulated Other Comprehensive Income/(Loss)		Total Thermo Fisher Scientific Inc. Shareholders’ Equity		Noncontrolling Interests		Total Equity
(In millions)			Shares		Amount					Shares			Amount

























				Three months ended March 28, 2026
Balance at December 31, 2025	$	122		445		$	445	$	18,563		$	59,156		69	$	(22,309)	$	(2,448)	$	53,407	$	7	$	53,415

Issuance of shares under stock plans	—			—		—		66			—			—	(22)		—		44		—		44
Stock-based compensation	—			—		—		83			—			—	—		—		83		—		83
Purchases of company common stock	—			—		—		—			—			5	(3,000)		—		(3,000)		—		(3,000)
Dividends declared ($0.47 per share)	—			—		—		—			(175)			—	—		—		(175)		—		(175)

Net income/(loss)	4			—		—		—			1,651			—	—		—		1,651		—		1,651
Other comprehensive income/(loss)	(6)			—		—		—			—			—	—		(49)		(49)		—		(49)
Contributions from (distributions to) noncontrolling interest	—			—		—		—			—			—	—		—		—		(1)		(1)
Excise tax from stock repurchases	—			—		—		—			—			—	(28)		—		(28)		—		(28)

Balance at March 28, 2026	$	121		445		$	445	$	18,713		$	60,632		74	$	(25,360)	$	(2,497)	$	51,934	$	7	$	51,940

				Three months ended March 29, 2025
Balance at December 31, 2024	$	120		444		$	444	$	17,962		$	53,102		63	$	(19,226)	$	(2,697)	$	49,584	$	(33)	$	49,551

Issuance of shares under stock plans	—			—		—		74			—			—	(24)		—		50		—		50
Stock-based compensation	—			—		—		75			—			—	—		—		75		—		75
Purchases of company common stock	—			—		—		—			—			4	(2,000)		—		(2,000)		—		(2,000)
Dividends declared ($0.43 per share)	—			—		—		—			(163)			—	—		—		(163)		—		(163)
Net income/(loss)	5			—		—		—			1,507			—	—		—		1,507		—		1,507
Other comprehensive income/(loss)	3			—		—		—			—			—	—		354		354		1		355
Contributions from (distributions to) noncontrolling interest	—			—		—		—			—			—	—		—		—		(1)		(1)
Excise tax from stock repurchases	—			—		—		—			—			—	(18)		—		(18)		—		(18)
Balance at March 29, 2025	$	128		444		$	444	$	18,111		$	54,447		67	$	(21,269)	$	(2,343)	$	49,390	$	(33)	$	49,357

The accompanying notes are an integral part of these condensed consolidated financial statements.

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 1. Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations

Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by helping them accelerate life sciences research, solve complex analytical challenges, increase laboratory productivity, and improve patient health through diagnostics and the development and manufacture of life-changing therapies. Markets served include pharmaceutical and biotech, academic and government, industrial and applied, as well as healthcare and diagnostics.

Interim Financial Statements

The interim condensed consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair statement of the financial position at March 28, 2026, the results of operations for the three-month periods ended March 28, 2026 and March 29, 2025, and the cash flows for the three-month periods ended March 28, 2026 and March 29, 2025. Interim results are not necessarily indicative of results for a full year.

The condensed consolidated balance sheet presented as of December 31, 2025, has been derived from the audited consolidated financial statements as of that date. The condensed consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes thereto of the company. The condensed consolidated financial statements and notes included in this report should be read in conjunction with the 2025 financial statements and notes included in the company’s Annual Report on Form 10-K. Certain reclassifications of prior year amounts have been made to conform to the current year presentation.

Note 1 to the consolidated financial statements for 2025 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no material changes in the company’s significant accounting policies during the three months ended March 28, 2026.

Amounts and percentages reported within these condensed consolidated financial statements are presented and calculated based on underlying unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.

The company’s estimates include, among others, asset reserve requirements as well as the amounts of future cash flows associated with certain assets and businesses that are used in assessing the risk of impairment. Actual results could differ from those estimates.

Recent Accounting Pronouncements

The following table provides a description of recent accounting pronouncements adopted and those standards not yet adopted with potential for a material impact on the company's financial statements or disclosures.


Standard	Description	Adoption timing and approach	Impact of adoption or other significant matters
Standards recently adopted


ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures	Among other things, new guidance to disclose additional information about the tax rate reconciliation and income taxes paid.	2025 annual report and interim periods thereafter using a prospective method.	Increased annual disclosures in Notes 7 and 9
Standards not yet adopted
ASU No. 2024-03, Income Statement–Reporting Comprehensive Income–Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses	New guidance to disclose specified information about certain costs and expenses.	2027 annual report and interim periods thereafter using a prospective or retrospective method.	Will increase disclosures in Note 6

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)


Standard	Description	Adoption timing and approach	Impact of adoption or other significant matters
ASU No. 2025-06, Intangibles–Goodwill and Other–Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software	Among other things, new guidance to modernize the accounting for costs to develop software for internal use.	2028 annual report and interim periods thereafter using a prospective, retrospective, or modified transition method; early adoption is permitted.	Currently evaluating adoption impact, timing, and method
ASU No. 2025-10, Government Grants (Topic 832): Accounting for Government Grants Received by Business Entities	Among other things, establishes guidance for the recognition, measurement, and presentation of government grants.	2029 using a retrospective, modified retrospective, or modified prospective approach; early adoption is permitted.	Currently evaluating adoption impact, timing, and method

Note 2. Supplemental Balance Sheet Information

Inventories

The components of inventories are as follows:


(In millions)	March 28, 2026		December 31, 2025
Raw materials	$	1,925	$	1,877
Work in process	942		889
Finished goods	2,629		2,659
Inventories	$	5,496	$	5,425

Contract-related Balances

Contract asset and liability balances are as follows:


(In millions)	March 28, 2026		December 31, 2025
Current contract assets, net	$	1,684	$	1,666
Noncurrent contract assets, net	1		1
Current contract liabilities	2,928		2,710
Noncurrent contract liabilities	1,034		1,183

In the three months ended March 28, 2026, the company recognized revenues of $1.29 billion that were included in the contract liabilities balance at December 31, 2025. In the three months ended March 29, 2025, the company recognized revenues of $1.36 billion that were included in the contract liabilities balance at December 31, 2024.

Remaining Performance Obligations

The aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of March 28, 2026, was $29.41 billion. The company will recognize revenues for these performance obligations as they are satisfied, approximately 52% of which is expected to occur within the next twelve months. Amounts expected to occur thereafter generally relate to contract manufacturing, clinical research and extended warranty service agreements, which typically have durations of three to five years.

Note 3. Debt and Other Financing Arrangements

The company’s debt and other financing arrangements are as follows:


	Effective interest rate at March 28,		March 28,		December 31,
(Dollars in millions)	2026		2026		2025

Commercial Paper	3.87	%	$	393	$	—

3.20% 3-Year Senior Notes, Due 1/21/2026 (euro-denominated)			—		587
1.40% 8.5-Year Senior Notes, Due 1/23/2026 (euro-denominated)			—		822
4.953% 3-Year Senior Notes, Due 8/10/2026	5.15	%	600		600
0.832% 1.5-Year Senior Notes, Due 9/7/2026 (Swiss franc-denominated)	1.13	%	513		517

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)


	Effective interest rate at March 28,		March 28,	December 31,
(Dollars in millions)	2026		2026	2025

5.00% 3-Year Senior Notes, Due 12/5/2026	5.25	%	1,000	1,000
1.45% 10-Year Senior Notes, Due 3/16/2027 (euro-denominated)	1.66	%	575	587
1.75% 7-Year Senior Notes, Due 4/15/2027 (euro-denominated)	1.97	%	691	705
1.054% 5-Year Senior Notes, Due 10/20/2027 (Japanese yen-denominated)	1.18	%	180	184
4.80% 5-Year Senior Notes, Due 11/21/2027	5.00	%	600	600
Floating Rate (EURIBOR + 0.280%) 2-Year Senior Notes, Due 12/1/2027 (euro-denominated)	2.52	%	1,151	1,175
0.790% 3-Year Senior Notes, Due 1/6/2028 (Swiss franc-denominated)	1.34	%	110	111
0.50% 8.5-Year Senior Notes, Due 3/1/2028 (euro-denominated)	0.77	%	921	940
1.6525% 4-Year Senior Notes, Due 3/7/2028 (Swiss franc-denominated)	1.79	%	413	416
0.77% 5-Year Senior Notes, Due 9/6/2028 (Japanese yen-denominated)	0.90	%	181	185
1.375% 12-Year Senior Notes, Due 9/12/2028 (euro-denominated)	1.46	%	691	705
1.75% 7-Year Senior Notes, Due 10/15/2028	1.89	%	700	700
5.00% 5-Year Senior Notes, Due 1/31/2029	5.24	%	1,000	1,000
1.125% 4-Year Senior Notes, Due 3/7/2029 (Swiss franc-denominated)	1.26	%	394	397
1.95% 12-Year Senior Notes, Due 7/24/2029 (euro-denominated)	2.08	%	806	822
2.60% 10-Year Senior Notes, Due 10/1/2029	2.74	%	900	900
1.279% 7-Year Senior Notes, Due 10/19/2029 (Japanese yen-denominated)	1.44	%	29	30
1.120% 5-Year Senior Notes, Due 1/6/2030 (Swiss franc-denominated)	1.25	%	293	295
4.977% 7-Year Senior Notes, Due 8/10/2030	5.12	%	750	750
0.80% 9-Year Senior Notes, Due 10/18/2030 (euro-denominated)	0.89	%	2,014	2,056
4.215% 5-Year Senior Notes, Due 2/12/2031	4.41	%	1,000	—
4.200% 5.5-Year Senior Notes Due 3/1/2031	4.41	%	500	500
0.875% 12-Year Senior Notes, Due 10/1/2031 (euro-denominated)	1.13	%	1,036	1,057
2.00% 10-Year Senior Notes, Due 10/15/2031	2.23	%	1,200	1,200
1.8401% 8-Year Senior Notes, Due 3/8/2032 (Swiss franc-denominated)	1.92	%	519	524
2.375% 12-Year Senior Notes, Due 4/15/2032 (euro-denominated)	2.55	%	691	705
4.473% 7-Year Senior Notes, Due 10/7/2032	4.62	%	750	750
1.49% 10-Year Senior Notes, Due 10/20/2032 (Japanese yen-denominated)	1.60	%	39	40
4.95% 10-Year Senior Notes, Due 11/21/2032	5.09	%	600	600
1.4175% 8-Year Senior Notes, Due 3/7/2033 (Swiss franc-denominated)	1.49	%	438	442
4.550% 7.3-Year Senior Notes, Due 6/15/2033	4.73	%	750	—
5.086% 10-Year Senior Notes, Due 8/10/2033	5.20	%	1,000	1,000
1.125% 12-Year Senior Notes, Due 10/18/2033 (euro-denominated)	1.21	%	1,726	1,762
5.20% 10-Year Senior Notes, Due 1/31/2034	5.34	%	500	500
3.65% 12-Year Senior Notes, Due 11/21/2034 (euro-denominated)	3.76	%	863	881
1.50% 12-Year Senior Notes, Due 9/6/2035 (Japanese yen-denominated)	1.58	%	134	137
4.794% 10-Year Senior Notes, Due 10/7/2035	4.91	%	750	750
3.628% 10-Year Senior Notes, Due 12/1/2035 (euro-denominated)	3.70	%	1,266	1,292
4.902% 10-Year Senior Notes, Due 2/12/2036	5.02	%	1,300	—
1.76% 10-Year Senior Notes, Due 3/3/2036 (Swiss franc-denominated)	1.81	%	363	—
2.0375% 12-Year Senior Notes, Due 3/7/2036 (Swiss franc-denominated)	2.10	%	407	410
1.520% 12-Year Senior Notes, Due 1/6/2037 (Swiss franc-denominated)	1.56	%	389	392
1.6524% 12-Year Senior Notes, Due 3/6/2037 (Swiss franc-denominated)	1.71	%	269	271
2.875% 20-Year Senior Notes, Due 7/24/2037 (euro-denominated)	2.94	%	806	822

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)


	Effective interest rate at March 28,		March 28,		December 31,
(Dollars in millions)	2026		2026		2025

4.894% 12-Year Senior Notes, Due 10/7/2037	5.00	%	500		500
1.90% 12-Year Senior Notes, Due 3/3/2038 (Swiss franc-denominated)	1.95	%	314		—
1.50% 20-Year Senior Notes, Due 10/1/2039 (euro-denominated)	1.73	%	1,036		1,057
2.01% 15-Year Senior Notes, Due 3/3/2041 (Swiss franc-denominated)	2.05	%	357		—
2.80% 20-Year Senior Notes, Due 10/15/2041	2.90	%	1,200		1,200
1.625% 20-Year Senior Notes, Due 10/18/2041 (euro-denominated)	1.78	%	1,439		1,468
2.069% 20-Year Senior Notes, Due 10/20/2042 (Japanese yen-denominated)	2.13	%	91		93
5.404% 20-Year Senior Notes, Due 8/10/2043	5.50	%	600		600
2.02% 20-Year Senior Notes, Due 9/6/2043 (Japanese yen-denominated)	2.06	%	181		185
5.30% 30-Year Senior Notes, Due 2/1/2044	5.37	%	400		400
1.49% 20-Year Senior Notes, Due 1/6/2045 (Swiss franc-denominated)	1.54	%	232		233
1.8975% 20-Year Senior Notes, Due 3/7/2045 (Swiss franc-denominated)	1.95	%	169		170
5.546% 20-Year Senior Notes, Due 2/12/2046	5.64	%	750		—
2.11% 20-Year Senior Notes, Due 3/3/2046 (Swiss franc-denominated)	2.18	%	169		—
4.10% 30-Year Senior Notes, Due 8/15/2047	4.23	%	750		750
1.875% 30-Year Senior Notes, Due 10/1/2049 (euro-denominated)	1.99	%	1,151		1,175
1.47% 25-Year Senior Notes, Due 1/6/2050 (Swiss franc-denominated)	1.49	%	409		413
2.00% 30-Year Senior Notes, Due 10/18/2051 (euro-denominated)	2.07	%	863		881
2.382% 30-Year Senior Notes, Due 10/18/2052 (Japanese yen-denominated)	2.43	%	208		212
2.06% 30-Year Senior Notes, Due 3/3/2056 (Swiss franc-denominated)	2.09	%	248		—
Other			1		1
Total borrowings at par value			43,267		39,459

Unamortized discount			(91)		(94)
Unamortized debt issuance costs			(229)		(194)
Total borrowings at carrying value			42,947		39,172
Finance lease liabilities			213		213
Less: Short-term obligations and current maturities			3,090		3,533
Long-term obligations			$	40,071	$	35,852

EURIBOR - Euro Interbank Offered Rate

The effective interest rates for the fixed-rate debt include the stated interest on the notes, the accretion of any discounts/premiums and the amortization of any debt issuance costs.

See Note 4 for fair value information pertaining to the company’s long-term borrowings.

Credit Facilities

The company has a revolving credit facility (the Facility) with a bank group that provides for up to $5.00 billion of unsecured multi-currency revolving credit. The Facility expires on January 7, 2028. The revolving credit agreement calls for interest at either a Term Secured Overnight Financing Rate (SOFR), EURIBOR-based rate (for funds drawn in euro), or a rate based on the prime lending rate of the agent bank, at the company’s option. The agreement contains affirmative, negative and financial covenants, and events of default customary for facilities of this type. The covenants in the Facility include a Consolidated Net Interest Coverage Ratio (Consolidated EBITDA to Consolidated Net Interest Expense), as such terms are defined in the Facility. Specifically, the company has agreed that, so long as any lender has any commitment under the Facility, any letter of credit is outstanding under the Facility, or any loan or other obligation is outstanding under the Facility, it will maintain a minimum Consolidated Net Interest Coverage Ratio of 3.5:1.0 as of the last day of any fiscal quarter. As of March 28, 2026, no borrowings were outstanding under the Facility.

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Commercial Paper Programs

The company has commercial paper programs pursuant to which it may issue and sell unsecured, short-term promissory notes (CP Notes). Under the U.S. program, a) maturities may not exceed 397 days from the date of issue and b) the CP Notes are issued on a private placement basis under customary terms in the commercial paper market and are not redeemable prior to maturity nor subject to voluntary prepayment. Under the euro program, maturities may not exceed 183 days and may be denominated in euro, U.S. dollars, Japanese yen, British pounds sterling, Swiss franc, Canadian dollars or other currencies. Under both programs, the CP Notes are issued at a discount from par (or premium to par, in the case of negative interest rates), or, alternatively, are sold at par and bear varying interest rates on a fixed or floating basis.

Senior Notes

Interest is payable annually on the euro and public Swiss franc-denominated fixed rate senior notes, quarterly on the euro-denominated floating rate senior note, and semi-annually on all other senior notes. Each of the U.S. dollar and euro-denominated fixed rate senior notes, and Japanese yen-denominated and Swiss franc-denominated private placement notes may be redeemed at a redemption price of 100% of the principal amount plus a specified make-whole premium and accrued interest, together with swap breakage costs payable to holders of the Japanese yen-denominated and Swiss franc-denominated private placement notes who have entered into cross-currency swap agreements. The company is subject to certain affirmative and negative covenants under the indentures and note purchase agreement governing the senior notes, the most restrictive of which limits the ability of the company to pledge certain property and assets as security under borrowing arrangements. The company was in compliance with all covenants related to its senior notes at March 28, 2026.

Thermo Fisher Scientific (Finance I) B.V. (Thermo Fisher International), a wholly-owned finance subsidiary of the company, issued each of the following notes outstanding as of March 28, 2026, included in the table above (collectively, the “Euronotes”) in registered public offerings: the Floating Rate Senior Notes due 2027, the 0.80% Senior Notes due 2030, the 1.125% Senior Notes due 2033, the 3.628% Senior Notes due 2035, the 1.625% Senior Notes due 2041, and the 2.00% Senior Notes due 2051. The company has fully and unconditionally guaranteed all of Thermo Fisher International’s obligations under the Euronotes and all of Thermo Fisher International’s other debt securities, and no other subsidiary of the company will guarantee these obligations. Thermo Fisher International is a “finance subsidiary” as defined in Rule 13-01(a)(4)(vi) of the Exchange Act, with no assets or operations other than those related to the issuance, administration and repayment of the Euronotes and other debt securities issued by Thermo Fisher International from time to time. The financial condition, results of operations and cash flows of Thermo Fisher International are consolidated in the financial statements of the company.

Note 4. Fair Value Measurements

Fair Value Measurements

The following tables present information about the company’s financial assets and liabilities measured at fair value on a recurring basis:


	March 28,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
(In millions)	2026		(Level 1)		(Level 2)		(Level 3)
Assets
Cash equivalents	$	137	$	137	$	—	$	—

Investments	110		25		—		85

Insurance contracts	266		—		266		—
Derivative contracts	780		—		780		—
Contingent consideration	67		—		—		67
Total assets	$	1,362	$	163	$	1,047	$	152

Liabilities
Derivative contracts	$	598	$	—	$	598	$	—
Contingent consideration	168		—		—		168
Total liabilities	$	767	$	—	$	598	$	168

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)


	December 31,		Quoted prices in active markets		Significant other observable inputs		Significant unobservable inputs
(In millions)	2025		(Level 1)		(Level 2)		(Level 3)
Assets
Cash equivalents	$	6,907	$	6,907	$	—	$	—
Bank time deposits	250		250		—		—
Investments	103		27		—		76

Insurance contracts	280		—		280		—
Derivative contracts	685		—		685		—
Contingent consideration	67		—		—		67
Total assets	$	8,292	$	7,184	$	966	$	143

Liabilities
Derivative contracts	$	506	$	—	$	506	$	—
Contingent consideration	16		—		—		16
Total liabilities	$	522	$	—	$	506	$	16

In the three-month periods ended March 28, 2026, and March 29, 2025, the company recorded $(1) million and $2 million, respectively, of net gains/(losses) on investments, which are included in other income/(expense) in the accompanying statements of income.

The following table provides a rollforward of investments classified as level 3:


	Three months ended
(In millions)		March 28, 2026		March 29, 2025
Investments
Beginning balance		$	76	$	21
Purchases		9		11


Ending balance		$	85	$	31

The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of a qualifying transaction), of the contingent consideration asset:


	Three months ended
(In millions)	March 28, 2026
Contingent consideration asset
Beginning balance	$	67


Changes in fair value included in earnings	1
Ending balance	$	67

The following table provides a rollforward of the fair value, as determined by level 3 inputs (such as likelihood of achieving production or revenue milestones, as well as changes in the fair values of the investments underlying a recapitalization investment portfolio), of the contingent consideration liabilities.


	Three months ended
(In millions)		March 28, 2026		March 29, 2025
Contingent consideration liabilities
Beginning balance		$	16	$	13
Acquisitions (including assumed balances)		153		—

Changes in fair value included in earnings		—		1
Ending balance		$	168	$	13

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Fair Value of Other Financial Instruments

The carrying value and fair value of the company’s debt instruments are as follows:


	March 28, 2026				December 31, 2025
(In millions)	Carrying value		Fair value		Carrying value		Fair value
Senior notes	$	42,554	$	39,354	$	39,171	$	36,606

Commercial paper	393		393		—		—
Other	1		1		1		1
	$	42,947	$	39,747	$	39,172	$	36,607

The fair value of debt instruments, excluding private placement notes, was determined based on quoted market prices and on borrowing rates available to the company at the respective period ends, which represent level 2 measurements. The fair value of private placement notes was determined based on internally developed pricing models and unobservable inputs, which represent level 3 measurements.

Note 5. Commitments and Contingencies

Environmental Matters

The company is currently involved in various stages of investigation and remediation related to environmental matters. The company cannot predict all potential costs related to environmental remediation matters and the possible impact on future operations given the uncertainties regarding the extent of the required cleanup, the complexity and interpretation of applicable laws and regulations, the varying costs of alternative cleanup methods and the extent of the company’s responsibility. Expenses for environmental remediation matters related to the costs of installing, operating and maintaining groundwater-treatment systems and other remedial activities related to historical environmental contamination at the company’s domestic and international facilities were not material in any period presented. At March 28, 2026, there have been no material changes to the accruals for pending environmental-related matters disclosed in the company’s 2025 financial statements and notes included in the company’s Annual Report on Form 10-K. While management believes the accruals for environmental remediation are adequate based on current estimates of remediation costs, the company may be subject to additional remedial or compliance costs due to future events such as changes in existing laws and regulations, changes in agency direction or enforcement policies, developments in remediation technologies or changes in the conduct of the company’s operations, which could have a material adverse effect on the company’s financial position, results of operations and cash flows.

Litigation and Related Contingencies

The company is involved in various disputes, governmental and/or regulatory inspections, inquiries, investigations and proceedings, and litigation matters that arise from time to time in the ordinary course of business. The disputes and litigation matters include product liability, intellectual property, employment and commercial issues. Due to the inherent uncertainties associated with pending litigation or claims, the company cannot predict the outcome, nor, with respect to certain pending litigation or claims where no liability has been accrued, make a meaningful estimate of the reasonably possible loss or range of loss that could result from an unfavorable outcome. The company has no material accruals for pending litigation or claims for which accrual amounts are not disclosed in these interim financial statements and notes, nor are material losses deemed probable for such matters. It is reasonably possible, however, that an unfavorable outcome that exceeds the company’s current accrual estimate, if any, for one or more such matters could have a material adverse effect on the company’s results of operations, financial position and cash flows.

Product Liability, Workers Compensation and Other Personal Injury Matters

The company is involved in various proceedings and litigation that arise from time to time in connection with product liability, workers compensation and other personal injury matters. At March 28, 2026, there have been no material changes to the accruals for pending product liability, workers compensation, and other personal injury matters disclosed in the company’s 2025 financial statements and notes included in the company’s Annual Report on Form 10-K. Although the company believes that the amounts accrued and estimated insurance recoveries are probable and appropriate based on available information, including actuarial studies of loss estimates, the process of estimating losses and insurance recoveries involves a considerable degree of judgment by management and the ultimate amounts could vary, which could have a material adverse effect on the company’s results of operations, financial position, and cash flows. Insurance contracts do not relieve the company of its primary obligation with respect to any losses incurred. The collectability of amounts due from its insurers is subject to the solvency and willingness of the insurer to pay, as well as the legal sufficiency of the insurance claims. Management monitors the payment history as well as the financial condition and ratings of its insurers on an ongoing basis.

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 6. Supplemental Income Statement Information

Disaggregated Revenues

Revenues by type are as follows:


	Three months ended

(In millions)		March 28, 2026		March 29, 2025
Revenues
Consumables		$	4,722	$	4,354
Instruments		1,555		1,626
Services		4,728		4,384
Consolidated revenues		$	11,005	$	10,364

Revenues by geographic region based on customer location are as follows:


	Three months ended


(In millions)		March 28, 2026		March 29, 2025
Revenues
North America		$	5,705	$	5,513
Europe		2,957		2,624
Asia-Pacific		1,970		1,891
Other regions		372		337
Consolidated revenues		$	11,005	$	10,364

Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions.

Revenues by business are as follows:


	Three months ended
(In millions)		March 28, 2026		March 29, 2025
Revenues
Biosciences		$	981	$	993
Genetic sciences		655		677
BioProduction		893		671
Other		107		—
Life Sciences Solutions		2,636		2,341
Chromatography and mass spectrometry		798		773
Chemical analysis		285		286
Electron microscopy		633		659

Analytical Instruments		1,716		1,718
Clinical diagnostics		271		263
ImmunoDiagnostics		230		217
Microbiology		160		152
Transplant diagnostics		121		113
Healthcare market channel		430		474
Elimination of intrasegment revenues		(71)		(72)
Specialty Diagnostics		1,142		1,148
Laboratory products		569		582
Research and safety market channel		1,827		1,727
Pharma services		1,741		1,607
Clinical research		2,128		1,939
Elimination of intrasegment revenues and other		(228)		(214)
Laboratory Products and Biopharma Services		6,036		5,640
Elimination of intersegment revenues		(524)		(482)
Consolidated revenues		$	11,005	$	10,364

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Restructuring and Other Costs

In the first three months of 2026, restructuring and other costs primarily included continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, impairment of long-lived assets, and, to a lesser extent, net charges for pre-acquisition litigation and other matters. In 2026, severance actions associated with facility consolidations and cost reduction measures affected less than 1% of the company’s workforce.

As of May 1, 2026, the company has identified restructuring actions, primarily in the Laboratory Products and Biopharma Services segment, that it expects will result in additional charges of approximately $290 million, primarily in 2026, and expects to identify additional actions in future periods.

Restructuring and other costs are as follows:


	Three months ended
(In millions)	March 28, 2026

Life Sciences Solutions	$	9
Analytical Instruments	4

Laboratory Products and Biopharma Services	33
Corporate	3
	$	49

The following table summarizes the changes in the company’s accrued restructuring balance, which is included in other accrued expenses in the accompanying balance sheets. Other amounts reported as restructuring and other costs in the accompanying statements of income have been summarized in the notes to the table.


(In millions)	Total (a)
Balance at December 31, 2025	$	70
Net restructuring charges incurred in 2026 (b)	34
Payments	(37)
Currency translation and other	(2)
Balance at March 28, 2026	$	65

(a)The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.

(b)Excludes $15 million of net charges, principally $14 million of charges for impairment of long-lived assets in the Laboratory Products and Biopharma Services segment.

The company expects to pay accrued restructuring costs primarily through 2026.

Earnings per Share

The company’s earnings per share are as follows:


	Three months ended
		March 28,		March 29,

(In millions except per share amounts)		2026		2025
Net income attributable to Thermo Fisher Scientific Inc.		$	1,651	$	1,507

Basic weighted average shares		372		378
Plus effect of: stock options and restricted stock units		1		1
Diluted weighted average shares		373		379

Basic earnings per share		$	4.44	$	3.99
Diluted earnings per share		$	4.43	$	3.98

Antidilutive stock options excluded from diluted weighted average shares		3		3

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 7. Income Taxes

The provision for income taxes in the accompanying statements of income differs from the provision calculated by applying the statutory federal income tax rate to income before provision for income taxes due to the following:


	Three months ended
(Dollars in millions)	March 28, 2026				March 29, 2025
U.S. federal statutory tax rate	$	364	21.0	%	$	340	21.0	%
State and local income taxes, net of federal income tax effect	21		1.2	%	14		0.8	%
Foreign tax effects	(150)		(8.7)	%	(43)		(2.6)	%



































Effect of changes in tax laws or rates enacted in the current period	—		0.0	%	2		0.1	%
Effect of cross-border tax laws	59		3.4	%	19		1.2	%






Tax credits	(46)		(2.6)	%	(45)		(2.8)	%


Changes in valuation allowances	—		0.0	%	(28)		(1.7)	%
Nontaxable or nondeductible items	—		0.0	%	(8)		(0.5)	%

Changes in unrecognized tax benefits	1		0.0	%	(28)		(1.7)	%
Other adjustments	(179)		(10.3)	%	(128)		(7.9)	%







Effective tax rate	$	70	4.0	%	$	95	5.8	%

In the first three months of 2026 and 2025, the company recorded deferred tax benefits from the recognition of a tax attribute related to domestication transactions of $175 million and $125 million, respectively, included in Other adjustments above.

The company has operations and a taxable presence in approximately 70 countries outside the U.S. The company's effective income tax rate differs from the U.S. federal statutory rate each year due to certain operations that are subject to tax incentives, state and local taxes, and foreign taxes that are different than the U.S. federal statutory rate.

On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was enacted. The OBBBA includes a broad range of provisions, such as the permanent extension of certain otherwise expiring provisions, modifications to the international tax framework and the reinstatement of favorable tax treatment for certain business provisions. The OBBBA made changes to certain US corporate tax provisions which are effective beginning in 2026. The enactment of the OBBBA does not have a material impact on the results from operations for the current year or future years.

Unrecognized Tax Benefits

As of March 28, 2026, the company had $0.42 billion of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. A reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:


(In millions)	2026
Balance at beginning of year	$	419


Additions for tax positions of current year	1




Balance at end of period	$	420

Note 8. Comprehensive Income/(Loss) and Shareholders' Equity

Comprehensive Income/(Loss)

Changes in each component of accumulated other comprehensive income/(loss), net of tax, are as follows:


(In millions)	Cumulative translation adjustment		Unrealized gains/(losses) on hedging instruments		Pension and other postretirement benefit liability adjustment		Total







	Three months ended March 28, 2026
Balance at December 31, 2025	$	(2,181)	$	(23)	$	(245)	$	(2,448)
Other comprehensive income/(loss) before reclassifications	(58)		—		2		(57)
Amounts reclassified from accumulated other comprehensive income/(loss)	6		1		1		8
Net other comprehensive income/(loss)	(53)		1		3		(49)
Balance at March 28, 2026	$	(2,234)	$	(22)	$	(242)	$	(2,497)

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Note 9. Supplemental Cash Flow Information

Supplemental cash flow information is as follows:


	Three months ended
(In millions)	March 28, 2026		March 29, 2025

Non-cash investing and financing activities
Acquired but unpaid property, plant and equipment	$	206	$	173



Declared but unpaid dividends	177		164
Issuance of stock upon vesting of restricted stock units	62		65
Excise tax from stock repurchases	28		18

Cash, cash equivalents and restricted cash is included in the accompanying balance sheet as follows:


(In millions)	March 28, 2026		December 31, 2025

Cash and cash equivalents	$	3,254	$	9,852
Restricted cash included in other current assets	4		5
Restricted cash included in other assets	22		22
Cash, cash equivalents and restricted cash	$	3,280	$	9,879

Amounts included in restricted cash primarily represent funds held as collateral for bank guarantees, pension related deposits, and incoming cash in China awaiting government administrative clearance.

Note 10. Derivatives

Derivative Contracts

The following table provides the aggregate notional value of outstanding derivative contracts.


(In millions)	March 28, 2026		December 31, 2025

Notional amount
Cross-currency interest rate swaps designated as net investment hedge - euro	$	—	$	1,000
Cross-currency interest rate swaps designated as net investment hedge - Japanese yen	4,650		4,650
Cross-currency interest rate swaps designated as net investment hedge - Swiss franc	8,800		5,000
Currency exchange contracts	1,286		2,248

While certain derivatives are subject to netting arrangements with counterparties, the company does not offset derivative assets and liabilities within the balance sheet. The following tables present the fair value of derivative instruments in the accompanying balance sheets and statements of income.


	Fair value – assets				Fair value – liabilities
	March 28,		December 31,		March 28,		December 31,
(In millions)	2026		2025		2026		2025
Derivatives designated as hedging instruments

Cross-currency interest rate swaps	$	778	$	684	$	597	$	504
Derivatives not designated as hedging instruments
Currency exchange contracts	2		2		1		2

Total derivatives	$	780	$	685	$	598	$	506

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The following table provides information on the company’s derivative positions subject to master netting arrangements, presented on a net basis, had the company elected to offset the asset and liability balances of its positions in the consolidated balance sheets:


	Fair value – assets				Fair value – liabilities
	March 28,		December 31,		March 28,		December 31,
(In millions)	2026		2025		2026		2025
Gross amounts recognized in the consolidated balance sheets	$	780	$	685	$	598	$	506
Gross amounts subject to offset in master netting arrangements not offset in the consolidated balance sheets	(444)		(319)		(444)		(319)
Total derivatives, net	$	337	$	366	$	155	$	187

The fair value of the cross-currency interest rate swaps is included in the accompanying balance sheets under the caption other current assets, other assets, other current liabilities, or other long-term liabilities. The fair value of the currency exchange contracts is included in the accompanying balance sheets under the captions other current assets or other accrued expenses.


		Gain/(loss) recognized
	Three months ended
		March 28,		March 29,
(In millions)		2026		2025

Derivatives designated as cash flow hedges
Interest rate swaps
Amount reclassified from accumulated other comprehensive income/(loss) to interest expense		$	(1)	$	(1)
Financial instruments designated as net investment hedges
Foreign currency-denominated debt and other payables
Included in cumulative translation adjustment within other comprehensive income/(loss)		222		(450)
Cross-currency interest rate swaps
Included in cumulative translation adjustment within other comprehensive income/(loss)		(55)		(119)
Included in interest expense		97		68
Derivatives not designated as hedging instruments
Currency exchange contracts
Included in cost of product revenues		1		1
Included in other income/(expense)		7		10

Gains and losses recognized on currency exchange contracts are included in the accompanying statements of income together with the corresponding, offsetting losses and gains on the underlying hedged transactions.

See Note 1 to the consolidated financial statements for 2025 included in the company’s Annual Report on Form 10-K for additional information on the company’s risk management objectives and strategies.

Note 11. Business Segment Information

Business Segment Information

The company’s financial performance is reported in four segments. During 2026, there have been no changes to the company’s basis of segmentation or in the basis of measurement of segment income. Other segment items included in the below tables consist of stock-based compensation and other incentive compensation expenses, allocations of corporate expenses and certain overhead expenses, as well as elimination of intersegment and intrasegment profits. Prior period segment expense amounts have been recast to reflect the method for allocating expenses to segments in the current period.

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

2026


	Three months ended March 28, 2026
(In millions)	Life Sciences Solutions		Analytical Instruments		Specialty Diagnostics		Laboratory Products and Biopharma Services		Total
Revenues
Revenues from external customers	$	2,219	$	1,667	$	1,124	$	5,995	$	11,005
Intersegment revenues	417		49		18		41		524
	2,636		1,716		1,142		6,036		11,529
Elimination of intersegment revenues									(524)
Consolidated revenues									$	11,005
Segment Income
Cost of revenues	1,004		876		657		4,757
Selling, general, and administrative expenses	496		313		177		597
Research and development expenses	131		139		44		15
Other segment items	50		34		(49)		(110)
Segment income	954		355		313		778		2,399
Unallocated amounts
Cost of revenues adjustments									(14)
Selling, general and administrative expenses adjustments									(43)
Restructuring and other costs									(49)
Amortization of acquisition-related intangible assets									(430)
Interest income									233
Interest expense									(354)
Other income/(expense)									(9)
Consolidated income before income taxes									$	1,734


(In millions)	Unallocated amounts		Life Sciences Solutions		Analytical Instruments		Specialty Diagnostics		Laboratory Products and Biopharma Services		Consolidated
Segment assets	$	98,434	$	3,490	$	3,104	$	1,332	$	6,921	$	113,281
Purchases of property, plant and equipment	28		20		36		35		259		376
Depreciation of property, plant and equipment	—		70		26		24		186		306

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

2025


	Three months ended March 29, 2025
(In millions)	Life Sciences Solutions		Analytical Instruments		Specialty Diagnostics		Laboratory Products and Biopharma Services		Total
Revenues
Revenues from external customers	$	1,954	$	1,677	$	1,130	$	5,603	$	10,364
Intersegment revenues	387		41		18		37		482
	2,341		1,718		1,148		5,640		10,846
Elimination of intersegment revenues									(482)
Consolidated revenues									$	10,364
Segment Income
Cost of revenues	855		835		679		4,410
Selling, general, and administrative expenses	468		313		171		588
Research and development expenses	139		137		45		13
Other segment items	45		33		(51)		(103)
Segment income	834		399		304		731		2,269
Unallocated amounts
Cost of revenues adjustments									(11)
Selling, general and administrative expenses adjustments									(14)
Restructuring and other costs									(98)
Amortization of acquisition-related intangible assets									(429)
Interest income									203
Interest expense									(303)
Other income/(expense)									3
Consolidated income before income taxes									$	1,620


(In millions)	Unallocated amounts		Life Sciences Solutions		Analytical Instruments		Specialty Diagnostics		Laboratory Products and Biopharma Services		Consolidated
Segment assets	$	85,272	$	3,018	$	2,986	$	1,298	$	6,467	$	99,041
Purchases of property, plant and equipment	36		43		44		33		205		362
Depreciation of property, plant and equipment	—		59		24		22		172		276

Note 12. Acquisitions and Divestiture

Acquisitions

The company’s acquisitions have historically been made at prices above the determined fair value of the acquired identifiable net assets, resulting in goodwill, primarily due to expectations of the synergies that will be realized by combining the businesses and the benefits that will be gained from the assembled workforces. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products and services; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products and services.

Acquisitions have been accounted for using the acquisition method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition.

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

2026

On March 24, 2026, the company acquired, within the Laboratory Products and Biopharma Services segment, Clario Holdings, Inc., a U.S.-based leading provider of endpoint data solutions for clinical trials. The acquisition expands the segment’s portfolio with the addition of highly complementary clinical research offerings, enabling customers to gain critical insights from patient data to improve decision-making, accelerate innovation and drive greater productivity. The goodwill recorded as a result of this business combination is not expected to be tax deductible.

The components of the preliminary purchase price and net assets acquired are as follows:


(In millions)	Clario
Purchase price
Cash paid	$	5,806
Debt settled	3,180
Purchase price payable	121
Fair value of contingent consideration	110
Cash acquired	(117)
	$	9,099

Net assets acquired
Definite-lived intangible assets
Customer relationships	$	2,481
Product technology	844
Trade names	19
Backlog	461
Goodwill	6,120
Net other assets/(liabilities)	392
Contract liabilities	(375)
Deferred tax assets/(liabilities)	(843)
	$	9,099

The preliminary allocation of the purchase price for the acquisition of Clario is based on the estimates of the fair value of the purchase price and net assets acquired and is subject to adjustment upon finalization, largely with respect to acquired intangible assets, contract liabilities and the related deferred taxes. Measurements of these items inherently require significant estimates and assumptions.

In 2026, the company also acquired, within the Analytical Instruments segment, two proteomics software companies including one in the U.S. and one in Germany, further strengthening our mass spectrometry and proteomics software capabilities.

The weighted-average amortization periods for definite-lived intangible assets acquired in 2026 are 20 years for customer relationships, 7 years for product technology, 3 years for trade names, and 3 years for backlog. The weighted-average amortization period for all definite-lived intangible assets acquired in 2026 is 15 years.

THERMO FISHER SCIENTIFIC INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

2025

On September 1, 2025, the company acquired, within the Life Sciences Solutions segment, our filtration and separation business, a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications, from Solventum Corporation. The business strengthens the segment’s bioproduction offerings with advanced filtration technologies that improve quality and efficiency across upstream and downstream workflows. In addition, its industrial filtration and membrane solutions will expand our reach into industries including battery, semiconductor and medical device manufacturing. The goodwill recorded as a result of this business combination is not expected to be tax deductible.

The components of the preliminary purchase price and net assets acquired are as follows:


(In millions)	Filtration and separation business
Purchase price
Cash paid	$	3,939
Fair value of contingent consideration	(66)
Cash acquired	(9)
	$	3,865

Net assets acquired
Property, plant and equipment	$	470
Definite-lived intangible assets
Customer relationships	1,116
Product technology	388
Trade names	51
Goodwill	2,068
Net other assets/(liabilities)	150
Deferred tax assets/(liabilities)	(377)
	$	3,865

The preliminary allocation of the purchase price for the acquisition of Solventum’s Filtration and Separation business is based on the estimates of the fair value of the purchase price and net assets acquired and is subject to adjustment upon finalization, largely with respect to acquired intangible assets, inventory and the related deferred taxes. Measurements of these items inherently require significant estimates and assumptions.

In addition, in 2025, the company acquired within the Laboratory Products and Biopharma Services segment, a sterile fill finishing and packaging facility to meet the growing demand from pharma and biotech customers for U.S. manufacturing capacity.

The weighted-average amortization periods for definite-lived intangible assets acquired in 2025 are 18 years for customer relationships, 19 years for product technology, and 15 years for trade names. The weighted-average amortization period for all definite-lived intangible assets acquired in 2025 is 18 years.

Divestiture

On April 27, 2026, the company entered into an agreement to sell its microbiology business to Astorg for approximately $1.075 billion, consisting of cash and a $50 million seller note. The business is part of the Specialty Diagnostics segment. The sale is subject to customary closing conditions and applicable regulatory approvals and is expected to close in the second half of 2026. The assets and liabilities of the microbiology business were as follows as of March 28, 2026:


(In millions)
Current assets	$	231
Long-term assets	758
Current liabilities	72
Long-term liabilities	59

THERMO FISHER SCIENTIFIC INC.

Previous: Cover and table of contents · Next: Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations